Re: Farmas USA
RVNC
Nota de Stifel de ayer noche:
Initiating coverage of Revance Therapeutics with a Buy Rating and $50 PT. The neurotoxin space — owned by Botox AGN — is finally evolving after years of innovation stagnation: everything from consumer marketing to value to product efficacy is getting a revamp. Unseating Botox may not be likely, but being the innovative product in a sea of “like” choices is an enviable position for RVNC, in our view. We estimate a procedure penetration of 20% share at peak, with potential for greater upside for both cosmetic and therapeutic.
Re: Farmas USA
TEVA
Teva Pharmaceutical Industries Limited is expected* to report earnings on 02/13/2019 before market open.
Re: Farmas USA
Los MACDs diarios de IBB y XBI empezando a mostrar el color rojo …
Re: Farmas USA
En el Spy estan aguantando como jabatos el 262, de perderlo no se, no se (de todos modos esperaran como siempre al cierre EU).
Re: Farmas USA
CNAT vamos que cerramos el gap
Re: Farmas USA
Pico unas cuantas a 4,1
TGTX 1h
Re: Farmas USA
hoy el charles schwab ha colocado HZNP SEM Y NXGN como recomendada dentro de small cap growth